Marco Davila, MD, PhD

Dr. Joshua Richter and Dr. Marco Davila discuss the rationale for incorporating CAR T-cell therapy earlier in the treatment course for relapsed/refractory multiple myeloma (RRMM).

Dr. Joshua Richter and Dr. Marco Davila present a case of a patient with relapsed/refractory multiple myeloma (RRMM) experiencing first relapse after initial therapy and discuss whether patients considered ineligible for autologous stem cell transplantation may still be candidates for CAR T-cell therapy.

Dr. Joshua Richter and Dr. Marco Davila discuss the essential role of multidisciplinary care and caregiver engagement in the management of relapsed/refractory multiple myeloma (RRMM), particularly for patients undergoing CAR T-cell therapy.

Dr. Joshua Richter and Dr. Marco Davila discuss how to counsel patients with relapsed/refractory multiple myeloma (RRMM) about recovery and long-term follow-up after CAR T-cell therapy.

Dr. Joshua Richter and Dr. Marco Davila discuss practical strategies for bridging therapy in relapsed/refractory multiple myeloma (RRMM) as patients transition to CAR T-cell therapy.

Dr. Joshua Richter and Dr. Marco Davila discuss the ideal timing for referral to a cellular therapy specialist for patients with relapsed/refractory multiple myeloma (RRMM).

Dr. Joshua Richter and Dr. Marco Davila discuss how clinicians determine the optimal timing for CAR T-cell therapy in relapsed/refractory multiple myeloma (RRMM), emphasizing that treatment decisions should be individualized rather than based solely on line of therapy.

Dr. Joshua Richter and Dr. Marco Davila examine how real-world evidence is shaping the use of CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) beyond the results of pivotal clinical trials.

Experts unpack relapsed myeloma sequencing—risk, refractoriness, and support—plus earlier CAR T and bispecifics shaping personalized care.

Experts unpack relapsed myeloma sequencing—risk factors, referrals, and earlier CAR‑T and bispecific therapies to personalize care and support patients.

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.

Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.

Marco Davila, MD, PhD, discusses how to shape the future of medicine with gene and cell therapy.